CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.

@article{Dairaghi2012CCR1BR,
  title={CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.},
  author={Daniel J. Dairaghi and Babatunde O. Oyajobi and Anjana Gupta and Brandon W. McCluskey and Shichang Miao and Jay P. Powers and Lisa C. Seitz and Yu Wang and Yibin Zeng and Penglie Zhang and Thomas J. Schall and Juan C. Jaen},
  journal={Blood},
  year={2012},
  volume={120 7},
  pages={1449-57}
}
The chemokine CCL3/MIP-1α is a risk factor in the outcome of multiple myeloma (MM), particularly in the development of osteolytic bone disease. This chemokine, highly overexpressed by MM cells, can signal mainly through 2 receptors, CCR1 and CCR5, only 1 of which (CCR1) is responsive to CCL3 in human and mouse osteoclast precursors. CCR1 activation leads to the formation of osteolytic lesions and facilitates tumor growth. Here we show that formation of mature osteoclasts is blocked by the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

The Role of Chemoattractant Receptors in Shaping the Tumor Microenvironment

BioMed research international • 2014
View 14 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 50 references

A novel role for CCL 3 ( MIP1 alpha ) in myelomainduced bone disease via osteocalcin downregulation and inhibition of osteoblast function

S Vallet, S Pozzi, K Patel
Leukemia • 2011

CCR1 as a target for multiple myeloma.

Expert opinion on therapeutic targets • 2011

Similar Papers

Loading similar papers…